The applicant has a funded research program in Leptin and Adipokine Physiology and is a Clinical Research Overseer at the BIDMC and the Joslin Diabetes Center. In addition, he has a well established track record in mentoring clinical researchers. The candidate's immediate goal is to determine the role leptin and other adipokines play in normal physiology and the pathophysiology of disease states in humans. His long-term goal is to further our understanding of adipokine biology which will eventually lead to new treatments for metabolic syndrome, diabetes, cardiovascular disease, and obesity-associated malignancies. In working towards these goals, the candidate has and will continue to be training and establishing a group of outstanding clinical investigators studying complementary aspects of energy homeostasis and metabolic disorders. A K24 award will enable the applicant to realize these goals by providing more protected time for both patient-oriented research and mentoring. The environment for this research is outstanding with many successful faculty involved in this general area of research across the Harvard Medical System. The PI has access to "state of the art" facilities in the General Clinical Research Center (GCRC) as well as ongoing large cohort studies including the Nurses Health Study and the Health Professionals Study. The indicative research protocols described herein involve the administration of recombinant human leptin in the context of GCRC-based, randomized, placebo-controlled trials, to subjects with hypothalamic amenorrhea or the HIV-associated metabolic syndrome and/or to healthy volunteers to study physiology outcomes, leptin signaling, and/or activation of hypothalamic centers by leptin in humans. Moreover, the PI is presenting some of his studies on the role of adiponectin as the link between obesity, insulin resistance and colon cancer, ranging from large observational cohort studies, to studies of human samples ex vivo, to molecular biology and mechanistic animal studies in the laboratory. The applicant is also actively participating in several other observational cohort studies as well as GCRC-based interventional studies on the treatment of obese diabetic subjects. Human obesity and its associated metabolic disorders are among the largest public health challenges of our time. Understanding the mechanisms underlying these disorders is key to finding safe and effective treatments.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24DK081913-05
Application #
8325619
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Hyde, James F
Project Start
2008-09-15
Project End
2013-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$121,782
Indirect Cost
$9,021
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Liu, Xiaowen; Hamnvik, Ole-Petter R; Chamberland, John P et al. (2014) Circulating alanine transaminase (ALT) and ?-glutamyl transferase (GGT), but not fetuin-A, are associated with metabolic risk factors, at baseline and at two-year follow-up: the prospective Cyprus Metabolism Study. Metabolism 63:773-82
Panagiotou, Grigorios; Mu, Lin; Na, Brian et al. (2014) Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism 63:1265-71
Moon, Hyun-Seuk; Batirel, Saime; Mantzoros, Christos S (2014) Alpha linolenic acid and oleic acid additively down-regulate malignant potential and positively cross-regulate AMPK/S6 axis in OE19 and OE33 esophageal cancer cells. Metabolism 63:1447-54
Huffman, Derek M; Augenlicht, Leonard H; Zhang, Xueying et al. (2013) Abdominal obesity, independent from caloric intake, accounts for the development of intestinal tumors in Apc(1638N/+) female mice. Cancer Prev Res (Phila) 6:177-87
Chamberland, John P; Berman, Reena L; Aronis, Konstantinos N et al. (2013) Chemerin is expressed mainly in pancreas and liver, is regulated by energy deprivation, and lacks day/night variation in humans. Eur J Endocrinol 169:453-62
Aronis, Konstantinos N; Chamberland, John P; Mantzoros, Christos S (2013) GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways. Metabolism 62:1279-86
Moon, Hyun-Seuk; Mantzoros, Christos S (2013) Adiponectin and metformin additively attenuate IL1*-induced malignant potential of colon cancer. Endocr Relat Cancer 20:849-59
Matarese, Giuseppe; La Rocca, Claudia; Moon, Hyun-Seuk et al. (2013) Selective capacity of metreleptin administration to reconstitute CD4+ T-cell number in females with acquired hypoleptinemia. Proc Natl Acad Sci U S A 110:E818-27
Thakkar, Bindiya; Aronis, Konstantinos N; Vamvini, Maria T et al. (2013) Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism 62:922-34
Moon, Hyun-Seuk; Dincer, Fadime; Mantzoros, Christos S (2013) Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7 hippocampal cell lines. Metabolism 62:1131-6

Showing the most recent 10 out of 57 publications